- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05580445
Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
A Phase Ib/II, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antineoplastic Activity of CT-707 in Combination With Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Yinghui Sun, PhD
- Phone Number: 86-10-88858616
- Email: yhsun@centaurusbio.com
Study Locations
-
-
-
Shanghai, China, 200120
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Xianjun Yu, PhD
- Phone Number: 13801669875
- Email: yuxianjun@fudanpci.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
For inclusion in this study, patients must fulfil the following criteria:
- Male or female (age of 18~75 years old).
- Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Patients must have a life expectancy of ≥ 3 months.
- Patients must have histologically or cytologically confirmed advanced pancreatic adenocarcinoma or poorly differentiated pancreatic carcinoma that is metastatic to distant sites.
- Patients are required to have measurable disease (RECIST v1.1), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan.
Patients must have adequate organ and marrow function as defined below:
Blood routine: Absolute neutrophil count (ANC) ≥ 1.5×10^9/L; Platelet count (PLT) ≥ 100×10^9/L; Hemoglobin (HGB) ≥ 90 g/L.
Liver function: Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 times upper limit of normal (ULN), total bilirubin (TBIL) ≤ 1.5 times ULN in patients without liver metastases; AST and ALT ≤ 5 times ULN, TBIL ≤3 times ULN in patients with liver metastases.
Renal function: Serum creatinine (Scr) ≤1.5 times ULN or creatinine clearance ≥60 mL/min/1.73 m2.
Coagulation function: Activated partial thromboplastin time (APTT) ≤ 1.5 times ULN; International Normalized ratio (INR) ≤ 1.5 times ULN.
- Patients must have recovered from any acute adverse events (except alopecia and peripheral neurotoxicity ≤ Grade 2).
- Patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after the trial; female participants must have a negative serum pregnancy test within 7 days prior to treatment.
Exclusion Criteria:
Patients must not enroll in this study if any of the following exclusion criteria are fulfilled:
- Patients who have received chemotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor therapy within 4 weeks prior to the first use of the study drug.
- Patients who have received clinical investigational drug or treatment within 4 weeks prior to the first use of the study drug.
- Patients who have received major surgery within 4 weeks or had minor surgery within 2 weeks before the first dose of administration.
- Patients who have previously received FAK inhibitor or programmed cell death protein 1/programmed cell death ligand 1 (PD-1/L1) antibody and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody are not eligible.
- Patients receiving any medications or substances that are known to be moderate to strong inhibitors or inducers of CYP3A4 and which cannot be discontinued at least 1 week prior to the first dose of administration .
- Patients who have active central nervous system (CNS)or leptomeningeal metastasis. However, participants who are asymptomatic, clinically stable, and did not require steroid therapy at least 4 weeks before the first dose of study treatment are eligible.
Patients who have cardiovascular and cerebrovascular diseases currently or within the last 6 months, including but not limited to:
I. Myocardial infarction; II. Unstable Angina pectoris; III. Cerebrovascular accident; IV. Other acute uncontrolled heart disease; Mean resting corrected QTc interval using the Fridericia formula (QTcF) > 470 msec/female and > 450 msec/male; Severe arrhythmias or abnormal cardiac conduction, such as ventricular arrhythmias requiring clinical intervention, degree ii-iii atrioventricular block, etc; Various factors that may increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, a family history of a first-degree relative with long QT syndrome or sudden unexplained death before the age of 40, receiving any medication with known QT prolongation; Left ventricular ejection fraction (LVEF) < 40 % within 4 weeks prior to the first use of the study drug; Hypertension remains uncontrolled after aggressive antihypertensive therapy. Uncontrolled hypertension was defined as systolic blood pressure > 185 mmHg and/or diastolic blood pressure > 110 mmHg measured on 3 repetitions at least 10 minutes apart.
- Patients suffering from conditions which are likely to adversely affect gastrointestinal motility (ulcerative disease, uncontrollable nausea, vomiting, diarrhea, or poor absorption syndrome).
- Any evidence of severe or uncontrolled systemic disease, active infection or active bleeding diatheses, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
- Patients have uncontrolled pleural, pericardial or abdominal effusion requiring drainage excluding those staying stable for at least two weeks after drainage.
- Patients have active autoimmune disease that requires systemic treatment (immunomodulatory drugs, corticosteroids, or immunomodulatory drugs) in the past 2 years.
- Patients with severely impaired lung functions such as pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia and drug-associated pneumonia.
- Patients have allergic reactions to any component of CT-707, toripalimab and gemcitabine, or with history of severe allergic reactions to other monoclonal antibodies or gemcitabine.
- Female patients who are pregnant or breast-feeding, or male or female patients of reproductive potential who are not employing an effective method of birth control.
- Patients with mental disorder, alcohol and/or drug dependence.
- The investigator considers that the subject has a history of serious systemic diseases or other reasons and is not suitable or not willing to participate in this clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose-escalation and dose-expansion
Dose-escalation study is designed to determine the dose-limiting toxicity (DLTs) and recommended phase II dose (RP2D).
Dose-expansion study is designed to evaluate the antitumor activity of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer.
|
Focal Adhesion Kinase (FAK) inhibitor
Other Names:
Programmed Death 1(PD-1) antibody
Other Names:
nucleoside inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended phase 2 dose (RP2D) of CT-707 in combination with toripalimab and gemcitabine
Time Frame: Up to 24 months
|
The RP2D will be determined from the maximum tolerated dose (MTD) found in the dose-escalation cohort.
The MTD is determined as the dose at which no more than one patient (out of six) experiences any drug-related toxicity (DLT)
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Up to 24 months
|
Characterization of the safety and tolerability as determined by changes in laboratory values and electrocardiograms
|
Up to 24 months
|
Pharmacokinetics (Cmax) for CT-707
Time Frame: Cycle 1 (each cycle is 21 days)
|
Defined as maximum observed plasma concentration
|
Cycle 1 (each cycle is 21 days)
|
Pharmacokinetics (Tmax) for CT-707
Time Frame: Cycle 1 (each cycle is 21 days)
|
Defined as time to maximum plasma concentration
|
Cycle 1 (each cycle is 21 days)
|
Pharmacokinetics (AUC0-t) for CT-707
Time Frame: Cycle 1 (each cycle is 21 days)
|
Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration
|
Cycle 1 (each cycle is 21 days)
|
Pharmacokinetics (t½) for CT-707
Time Frame: Cycle 1 (each cycle is 21 days)
|
Defined as the apparent plasma terminal phase disposition half-life
|
Cycle 1 (each cycle is 21 days)
|
Overall response rate (ORR) as assessed by RECIST 1.1 criteria
Time Frame: Up to 24 months
|
Preliminary measure of anti-tumor activity of CT-707 in combination with toripalimab and gemcitabine
|
Up to 24 months
|
Progression free survival (PFS) according to RECIST v1.1 criteria
Time Frame: Up to 24 months
|
Preliminary measure of anti-tumor activity of CT-707 in combination with toripalimab and gemcitabine
|
Up to 24 months
|
Disease control rate (DCR) according to RECIST v1.1
Time Frame: Up to 24 months
|
Preliminary measure of anti-tumor activity of CT-707 in combination with toripalimab and gemcitabine
|
Up to 24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predictive biomarkers for response to the combination of CT-707, toripalimab and gemcitabine
Time Frame: Up to 24 months
|
To assess putative predictive biomarkers such as PD-L1 and p-FAK
|
Up to 24 months
|
Collaborators and Investigators
Investigators
- Study Director: Yinghui Sun, PhD, Shouyao Holdings (Beijing) Co. LTD
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Conteltinib
- Gemcitabine
Other Study ID Numbers
- CT-707-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Pancreatic Cancer
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
Danae Hamouda, MDRecruitingAdvanced Solid Tumor | Advanced Pancreatic CancerUnited States
-
Rui-hua Xu, MD, PhDNot yet recruitingAdvanced Pancreatic CancerChina
-
Mayo ClinicNational Cancer Institute (NCI)CompletedAdvanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma | Pancreatic Neoplasm | Locally Advanced Pancreatic CarcinomaUnited States
-
Istituto Scientifico Romagnolo per lo Studio e...CompletedUnresectable Pancreatic Cancer | Locally Advanced Pancreatic Cancer | Nonmetastatic Pancreatic CancerItaly
-
University of UtahNational Cancer Institute (NCI)Active, not recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal...United States
-
Centre Leon BerardRecruitingMetastatic Pancreatic Cancer | Advanced Pancreatic CancerFrance
-
National Cancer Institute (NCI)SuspendedStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Unresectable Pancreatic AdenocarcinomaUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI)RecruitingCervical Cancer | Pancreatic Cancer | Pancreas Cancer | Locally Advanced Cervical Carcinoma | Locally Advanced Cervical Cancer | Cancer of the Pancreas | Locally Advanced Pancreatic Carcinoma | Locally Advanced Pancreatic Cancer | Cancer of the Cervix | Locally Advanced Pancreas CancerUnited States
-
Azienda Ospedaliero-Universitaria di ModenaRecruitingMetastatic Pancreatic Cancer | Advanced Pancreatic CancerItaly
Clinical Trials on CT-707
-
Centaurus Biopharma Co., Ltd.UnknownNon-small Cell Lung CancerChina
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Recruiting
-
Agenus Inc.Completed
-
Agenus Inc.CompletedHerpes Simplex Type 2United States
-
SanofiActive, not recruitingMalignant Melanoma | Squamous Cell Carcinoma of SkinGermany, Spain, France, Chile, United States, Australia, Italy
-
SanofiMerck Sharp & Dohme LLCActive, not recruitingDiffuse Large B-cell Lymphoma | Classic Hodgkin LymphomaChile, Spain, Argentina
-
Northwell HealthToshiba America Medical Systems, Inc.Enrolling by invitationCoronary Artery Disease | Chest Pain | Acute Coronary Syndrome | Acute Myocardial InfarctionUnited States
-
CelltrionCompleted
-
University of PittsburghTerminatedCarcinoma, Squamous Cell of Head and NeckUnited States
-
Northwell HealthHeartFlow, Inc.CompletedAngina, Stable Chest Pain